At a glance
- Originator BC Cancer Agency; Precision NanoSystems
- Class Antimalarials; Antivirals; Chlorobenzenes; Disease-modifying antirheumatics; Ethanolamines; Quinolines; Small molecules
- Mechanism of Action Autophagy inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Cancer in Canada (unspecified route) (before September 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in Canada
- 28 Apr 2016 Chemical structure information added